Clinical trials: Breakthrough Infection
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Invasive Mold Infections, Breakthrough Invasive Mold Infections
Breakthrough Invasive Mold Infections Under Posaconazole Prophylaxis (BIMI)
Invasive mold infections (IMI) mainly affect patients with hematologic malignancies receiving intensive chemotherapy or after hematopoietic stem cell transplantation (HSCT).
- Conditions
- Invasive Mold Infections, Breakthrough Invasive Mold Infections, Hematologic Malignancy, Hematologic Diseases
- Trial name
- BIMI (NCT04720144)
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Vaccine Breakthrough Infections
Evaluation of the Consequences of Poly Vaccination on Innate Immunity : Applications to a Military Population
In this study, the poly vaccination of military personnel prior to deployment will be analyzed in terms of central, peripheral and long-lasting changes in innate immunity.
- Trial name
- VaxInnate (NCT06110741)
- Testing
- Blood and saliva sampling, Survey
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
Varicella
Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients
This study is conducted in order to collect clinical samples from patients who are diagnosed of having chickenpox infection. The results of this study will provide basic scientific information about chickenpox disease.
- Trial name
- NCT00127608
- Testing
- Collection of clinical samples
- Where
- Czechia
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Fungal Disease
A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
The goal of this observational study is to evaluate the efficacy the favorable response rate and safety of L-AmB(liposomal amphotericin B) for the treatment of br-IFD(breakthrough invasive fungal disease) in Chinese children and…
- Trial name
- NCT07357038
- Testing
- Patients received the Drug: liposomal amphotericin B（AmBisome） for treatment
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
COVID-19 Pneumonia, COVID-19
COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
A novel coronavirus, SARS-CoV-2 (formerly known as the 2019 novel coronavirus [2019-nCoV]) was identified as the agent that caused an outbreak of pneumonia (termed COVID-19) in Wuhan, China in December 2019.
- Trial name
- NCT05392075
- Testing
- Pfizer COVID-19 mRNA vaccine, Moderna COVID-19 mRNA vaccine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Methodist Health System
Cytomegalovirus Infections, Cytomegalovirus Viremia
HCMV Breakthrough Infections During Letermovir Prophylaxis
The goal of this clinical trial is to compare two strategies to monitor human cytomegalovirus (HCMV) infections in transplanted patients receiving letermovir (LTV) as anti-HCMV prophylaxis.
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Viremia, Hematopoietic Stem Cell Transplantation
- Trial name
- CMVbreak (NCT06339892)
- Testing
- Determination of HCMV DNA in plasma after DNAse digestion., Determination of HCMV DNA in blood or plasma.
- Where
- 8 sites in Italy
- Volunteers
- 140 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
COVID 19
Singapore SARS-CoV-2 Human Challenge Study
The goal of this study is to conduct a safe SARS-CoV-2 Delta variant human infection challenge in adult healthy volunteers. The main objectives are to: Induce laboratory confirmed infection in up to 70% of participants Confirm…
- Trial name
- Sing-CoV (NCT06654973)
- Testing
- GMP-produced SARS-CoV-2 Delta strain
- Where
- Singapore
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
HIV-1
Follow up of Thai Adult Volunteers With Breakthrough HIV Infection After Participation in a Preventive HIV Vaccine Trial
This protocol will study the clinical course of HIV-infection among volunteers who have received either a placebo injection or the experimental vaccine combination of ALVAC-HIV and AIDSVAX B/E prior to HIV-1 infection in…
- Trial name
- NCT00337181
- Where
- Thailand
- Volunteers
- 114 people
- Sponsor
- U.S. Army Medical Research and Development Command
Covid19
Covid-19 Infection in After Vaccination
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in Wuhan, China. It rapidly spread, resulting a global pandemic in March 2020.
- Trial name
- NCT05033834
- Testing
- covid-19 vaccines registered in Egypt
- Where
- 3 sites in Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia
Long-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005
This is a single-center, open-label, prospective observational extension of Study 311-HPV-1005 (NCT04965350). The study follows females who received at least one dose of a bivalent human papillomavirus vaccine containing HPV-16…
- Trial name
- NCT07833852
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Invasive Fungal Disease
Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases
This is a prospective, open label, controlled, single center real-world observational study. Adult (aged ≥ 18 years) patients with hematological malignancies develop breakthrough invasive fungal disease after receiving ≥ 7 days…
- Trial name
- NCT07135778
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
COVID-19, Breakthrough Infection
The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine
The severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) specific antibody and neutralizing antibody level induced by adenovirus vector vaccines were lower than mRNA vaccines.
- Trial name
- NCT05132855
- Testing
- BNT162b2, mRNA-1273, MVC-COV1901
- Where
- Taiwan
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Cytomegalovirus Infections
Breakthrough CMV Lung Transplant -Multicentre
Cytomegalovirus (CMV) infection is the most common opportunistic infection in lung transplantation leading to direct and indirect effects that can result in life threatening complications.
- Trial name
- NCT04439916
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Alberta
SARS CoV 2 Infection, Vaccination; Infection
Monitoring COVID-19 Vaccination Response in Fragile Populations
The present study is part of ORCHESTRA project, a three-year international research project aimed at tackling the coronavirus pandemic.
- Conditions
- SARS CoV 2 Infection, Vaccination; Infection, Breakthrough Infection
- Trial name
- ORCHESTRA-4 (NCT05222139)
- Testing
- COVID-19 vaccination
- Where
- 20 sites in Argentina, Gabon and 5 more
- Volunteers
- 8,894 people
- Sponsor
- University of Bologna
Chronic Hepatitis B Virus Treatment
Resistance to Lamivudine in HBV Egyptian Patients
On treatment parameters for Lamivudine resistance in HBV treated Egyptian patients
- Trial name
- NCT01548820
- Where
- Egypt
- Volunteers
- 230 people
- Sponsor
- Ain Shams University
Immunocompromised, Immunosuppressed
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States
This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
- Conditions
- Immunocompromised, Immunosuppressed, Covid-19, SARS-COV-2
- Trial name
- NCT05020145
- Testing
- BNT162b2 (Tozinameran)
- Where
- United States
- Volunteers
- 1,277,747 people
- Sponsor
- Pfizer
Covid19
The Impact of Vaccination on Severity of Illness in COVID-19
With the FDA's emergency use authorization declaration in December of 2020, the Pfizer-BioNtech vaccine became the first of several vaccines to kick off the mass vaccination effort across the United States against CoronaVIrus…
- Trial name
- NCT04912700
- Testing
- COVID-19 vaccine
- Where
- United States
- Volunteers
- 11,834 people
- Sponsor
- Corewell Health East
Prophylaxis, Stem Cell Transplant Complications
Ciprofloxacin Versus Levofloxacin in Stem Cell Transplant
Ciprofloxacin and levofloxacin are both in guidelines to use for prophylaxis in autologous and allogeneic Stem cell transplant.Ciprofloxacin was recently replaced by levofloxacin as the preferred agent in some transplant centers.
- Trial name
- NCT03850379
- Testing
- Levofloxacin, Ciprofloxacin
- Where
- United States
- Volunteers
- 308 people
- Sponsor
- Henry Ford Health System
COVID-19
IH Convidecia as Second Booster Dose Against Breakthrough Infections
This will be a randomized single-blind controlled trial to determine the immunogenicity, efficacy and safety of IH Convidecia (CanSino), as a second booster vaccination against Omicron and other emerging VOCs to prevent…
- Trial name
- NCT05517642
- Testing
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), mRNA vaccine BNT162b2 (Pfizer)
- Where
- Malaysia
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.